[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2640 followers Created: 2025-07-24 11:02:38 UTC $ANNX Enrollment in pivotal Phase X ARCHER II trial of Vonaprument (formerly ANX007) for Dry AMD with Geographic Atrophy completed by Annexon. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$annx](/topic/$annx) [advanced micro devices](/topic/advanced-micro-devices) [stocks technology](/topic/stocks-technology) [Post Link](https://x.com/OzmosiHealth/status/1948338024838013218)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2640 followers
Created: 2025-07-24 11:02:38 UTC
$ANNX Enrollment in pivotal Phase X ARCHER II trial of Vonaprument (formerly ANX007) for Dry AMD with Geographic Atrophy completed by Annexon.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
Related Topics $pph $xph $ibb $xbi more info $annx advanced micro devices stocks technology
/post/tweet::1948338024838013218